Skip to main content
Have a personal or library account? Click to login
Immunomodulatory effects of anti-estrogenic drugs Cover

Immunomodulatory effects of anti-estrogenic drugs

Acta Pharmaceutica
Volume 62 (2012): Issue 2 (June 2012)
By:  and    
Open Access
|Jun 2012
References

References

  1. A. Ray and A. B. Mitra, Estrogen and breast cancer,(2003) 13-24.
    Search in Google Scholar
  2. M. N. Okobia and C. H. Bunker, Epidemiological risk factors for breast cancer - a review,(2005) 35-42.
    Search in Google Scholar
  3. T. Suzuki, Y. Miki, N. Ohuchi and H. Sasano, Intratumoral estrogen production in breast carcinoma: significance of aromatase,(2008) 270-277; DOI: 10.1007/s12282-008-0062-z.
    Open DOISearch in Google Scholar
  4. I. Czajka-Oraniec and E. R. Simpson, Aromatase research and its clinical significance,(2010) 126-134.
    Search in Google Scholar
  5. W. C. Park and V. C. Jordan, Selective estrogen receptor modulators (SERMs) and their roles in breast cancer prevention,(2002) 82-88; DOI: 10.1016/S1471-4914(02)02282-7.
    Open DOISearch in Google Scholar
  6. G. T. Beatson, On the treatment of inoperable cases of carcinoma of the mamma: Suggestions for a new treatment with illustrative cases,(1896) 104-107; DOI: 10.1016/S0140-6736(01)72384-7.
    Open DOISearch in Google Scholar
  7. W. R. Miller, Oestrogens and breast cancer: biological considerations,(1991) 470-483.
    Open DOISearch in Google Scholar
  8. V. C. Jordan and W. J. Gradishar,, in(Ed. M. R. Alison), Vol. 2, Nature Publishing Group, London 2002, pp. 1449-1464.
    Search in Google Scholar
  9. P. Lonning, C. Pfister, A. Martoni and C. Zamagni, Pharmacokinetics of third-generation aromatase inhibitors,Suppl. 14 (2003) 23-32; DOI: 10.1016/S0093-7754(03)00305-1.
    Open DOISearch in Google Scholar
  10. R. Stuart-Harris and A. Davis, Optimal adjuvant endocrine therapy for early breast cancer,(2010) 383-398; DOI: 10.2217/whe.10.25.
    Open DOISearch in Google Scholar
  11. T. Delozier, Hormonal treatment in breast cancer,, Suppl. 8 (2010) F71-78; DOI: 10.1016/j.jgyn.2010.10.004.
    Open DOISearch in Google Scholar
  12. D. P. McDonnell and S. E. Wardell, The molecular mechanisms underlying the pharmacological actions of ER modulators: implications for new drug discovery in breast cancer,(2010) 620-628; DOI: 10.1016/j.coph.2010.09.007.
    Open DOISearch in Google Scholar
  13. F. Lumachi, G. Luisetto, S. M. Basso, U. Basso, A. Brunello and V. Camozzi, Endocrine therapy of breast cancer,(2011) 513-522; DOI: 10.2174/092986711794480177.
    Open DOISearch in Google Scholar
  14. A. Thomsen and J. M. Kolesar, Chemoprevention of breast cancer,(2008) 2221-2228; DOI: 10.2146/ajhp070663.
    Open DOISearch in Google Scholar
  15. C. Rivera-Guevara and J. Camacho, Tamoxifen and its new derivatives in cancer research,(2011) 237-245.
    Open DOISearch in Google Scholar
  16. R. Weinshilboum, Pharmacogenomics of endocrine therapy in breast cancer,(2008) 220-231; DOI: 10.1007/978-0-387-78818-0_14.
    Open DOISearch in Google Scholar
  17. H. Brauch, T. E. Mürdter, M. Eichelbaum and M. Schwab, Pharmacogenomics of tamoxifen therapy,(2009) 1770-1782; DOI: 10.1373/clinchem.2008.121756.
    Open DOISearch in Google Scholar
  18. R. Clarke, F. Leonessa, J. N. Welch and T. C. Skaar, Cellular and molecular pharmacology of antiestrogen action and resistance,(2001) 25-71.
    Search in Google Scholar
  19. A. Ring and M. Dowsett, Mechanisms of tamoxifen resistance,(2004) 643-658; DOI: 10.1677/erc.1.00776.
    Open DOISearch in Google Scholar
  20. C. M. Joffroy, M. B. Buck, M. B. Stope, S. L. Popp, K. Pfizenmaier and C. Knabbe, Antiestrogens induce transforming growth factor beta-mediated immunosuppression in breast cancer,(2010) 1314-1322; DOI: 10.1158/0008-5472.CAN-09-3292.
    Open DOISearch in Google Scholar
  21. S. Rotstein, H. Blomgren, B. Petrini, J. Wasserman and L. V. von Stedingk, Influence of adjuvant tamoxifen on blood lymphocytes,(1988) 75-79; DOI: 10.1007/BF01805743.
    Open DOISearch in Google Scholar
  22. E. Robinson, D. Rubin, T. Mekori, R. Segal and S. Pollack, In vivo modulation of natural killer cell activity by tamoxifen in patients with bilateral primary breast cancer,(1993) 209-212; DOI: 10.1007/BF01525437.
    Open DOISearch in Google Scholar
  23. P. Mallmann and D. Krebs, Effect of tamoxifen on parameters of cell-mediated immunity in post-menopausal patients with breast carcinoma,(1991) 689-696.
    Search in Google Scholar
  24. J. Lukac, Z. Kusic, D. Kordic, M. Koncar and A. Bolanca, Natural killer cell activity, phagocytosis, and number of peripheral blood cells in breast cancer patients treated with tamoxifen,(1994) 279-285; DOI: 10.1007/BF00666482.
    Open DOISearch in Google Scholar
  25. M. E. Sabbioni, M. Castiglione, C. Hürny, H. P. Siegrist, M. Bacchi, J. Bernhard, B. Thürlimann, H. Bonnefoi, L. Perey, A. Goldhirsch and H. J. Senn, Interaction of tamoxifen with concurrent cytotoxic adjuvant treatment affects lymphocytes and lymphocyte subsets counts in breast cancer patients,(1999) 149-153; DOI: 10.1007/s005200050245.
    Open DOISearch in Google Scholar
  26. E. Baral, E. Nagy, G. V. Krepart, R. J. Lotocki, H. W. Unruh and I. Berczi, Antiestrogens sensitize human ovarian and lung carcinomas for lysis by autologous killer cells,(2000) 2027-2031.
    Search in Google Scholar
  27. E. Baral, E. Nagy, L. Kangas and I. Berczi, Anti-estrogens enhance the therapeutic effect of lymphokine-activated killer cells on the P815 murine mastocytoma,(1996) 580-585; DOI: 10.1002/(SICI)1097-0215(19960807).
    Search in Google Scholar
  28. E. Baral, E. Nagy, L. Kangas and I. Berczi, Combination immunotherapy of the P815 murine mastocytoma with killer cells, IL-2 and anti-estrogens,(1997) 3653-3658.
    Search in Google Scholar
  29. S. Kumru, F. M. Yildiz, A. Godekmerdan, S. Kutlu, B. Yilmaz and B. Gurates, Effects of raloxifene and hormone replacement therapy on serum Th2 and Th3 type cytokine concentrations in healthy postmenopausal women: a randomised controlled trial,(2008) 489-493; DOI: 10.1007/s00404-007-0521-3.
    Open DOISearch in Google Scholar
  30. Y. Zhang, S. Saha, G. Rosenfeld, J. Gonzalez, K. P. Pepeljugoski and E. Peeva, Raloxifene modulates estrogen-mediated B cell autoreactivity in NZB/W F1 mice,(2010) 1646-1657; DOI: 10.3899/jrheum.090911.
    Open DOISearch in Google Scholar
  31. G. Nalbandian, V. Paharkova-Vatchkova, A. Mao, S. Nale and S. Kovats, The selective estrogen receptor modulators, tamoxifen and raloxifene, impair dendritic cell differentiation and activation,(2005) 2666-2675.
    Open DOISearch in Google Scholar
  32. M. A. García-Pérez, R. Del Val, I. Noguera, C. Hermenegildo, B. Pineda, A. Martinez-Romero and A. Cano, Estrogen receptor agonists and immune system in ovariectomized mice,(2006) 807-819.
    Open DOISearch in Google Scholar
  33. M. C. Erlandsson, E. Gomori, M. Taube and H. Carlsten, Effects of raloxifene, a selective estrogen receptor modulator, on thymus, T cell reactivity, and inflammation in mice,(2000) 103-109; DOI: 10.1006/cimm.2000.1719.
    Open DOISearch in Google Scholar
  34. H. Masuoka, M. Mori, N. Nomura, M. Sakurai, K. Yoshida, N. Usuda, H. Shirai, I. Shimokawara and K. Asaishi, Assessment of post-administration body distribution of toremifene and tamoxifen, and their administration regimens,(2002) 881-887.
    Search in Google Scholar
  35. S. M. Haeryfar, E. Nagy, E. Baral, G. V. Krepart, R. J. Lotocki and I. Berczi, Antiestrogens affect both pathways of killer cell-mediated oncolysis,(2000) 1849-1853.
    Search in Google Scholar
  36. J. Komi and O. Lassila, Antioestrogens enhance tumour necrosis factor receptor 2 (TNF-R2) expression and TNF-R2-mediated proliferation in activated T cells,(1998) 254-260; DOI: 10.1046/j.1365-3083.1998.00388.x.
    Open DOISearch in Google Scholar
  37. J. Teodorczyk-Injeyan, M. Cembrzynska-Nowak, S. Lalani and J. A. Kellen, Modulation of biological responses of normal human mononuclear cells by antiestrogens,.(1993) 279-283.
    Search in Google Scholar
  38. J. A. Kellen, The effect of toremifene on the expression of some genes in human mononuclear cells,(1995) 215-217.
    Search in Google Scholar
  39. L. S. Järvinen, S. Pyrhönen, K. J. Kairemo and T. Paavonen, The effect of anti-oestrogens on cytokine production in vitro,(1996) 15-20; DOI: 10.1046/j.1365-3083.1996.d01-85.x.
    Open DOISearch in Google Scholar
  40. P. Pal, J. K. Kanaujiya, S. Lochab, S. B. Tripathi, M. L. Bhatt, P. K. Singh, S. Sanyal and A. K. Trivedi, 2-D gel electrophoresis-based proteomic analysis reveals that ormeloxifen induces G0-G1 growth arrest and ERK-mediated apoptosis in chronic myeloid leukemia cells K562,(2011) 1517-1529; DOI: 10.1002/pmic.201000720.
    Open DOISearch in Google Scholar
  41. L. Thomas, M. Asad, H. J. Hrishikeshavan and G. K. Chandrakala, Effect of centchroman on cellular and humoral immunity,(2007) 387-394.
    Search in Google Scholar
  42. A. Purohit, A. Singh, M. W. Ghilchik, O. Serlupi-Crescenzi and M. J. Reed, Inhibition of IL-6+ IL-6 soluble receptor-stimulated aromatase activity by the IL-6 antagonist, Sant 7, in breast tissue-derived fibroblasts,(2003) 630-635; DOI: 10.1038/sj.bjc.6600785.
    Open DOISearch in Google Scholar
  43. P. G. Morris, C. A. Hudis, D. Giri, M. Morrow, D. J. Falcone, X. K. Zhou, B. Du, E. Brogi, C. B. Crawford, L. Kopelovich, K. Subbaramaiah and A. J. Dannenberg, Inflammation and increased aromatase expression occur in the breast tissue of obese women with breast cancer,(2011) 1021-1029; DOI: 10.1158/1940-6207.CAPR-11-0110.
    Open DOISearch in Google Scholar
  44. J. Berry, B. J. Green and D. S. Matheson, Modulation of natural killer cell activity in stage I post-menopausal breast cancer patients on low-dose aminoglutethimide,(1987) 72-75; DOI: 10.1007/BF00199836.
    Open DOISearch in Google Scholar
  45. H. van Dijk and H. E. Jacobse-Geels, Evidence for the involvement of corticosterone in the ontogeny of the cellular immune apparatus of the mouse,(1978) 637-642.
    Search in Google Scholar
  46. M. D. Coleman, L. F. Khalaf and P. J. Nicholls, Aminoglutethimide-induced leukopenia in a mouse model: effects of metabolic and structural determinants,(2003) 27-32; DOI: 10.1016/j.etap.2003.08.003.
    Open DOISearch in Google Scholar
  47. M. J. Cannon, M. G. Petroff and J. L. Pate, Effects of prostaglandin F2alpha and progesterone on the ability of bovine luteal cells to stimulate T lymphocyte proliferation,(2003) 695-700; DOI: 10.1095/?biolreprod.103.017590.
    Open DOISearch in Google Scholar
  48. D. P. Braun, K. A. Crist, F. Shaheen, E. D. Staren, S. Andrews and J. Parker, Aromatase inhibitors increase the sensitivity of human tumor cells to monocyte-mediated, antibody-dependent cellular cytotoxicity,(2005) 570-571; DOI: 10.1016/j.amjsurg.2005.06.013.
    Open DOISearch in Google Scholar
  49. C. P. Schneider, E. A. Nickel, T. S. Samy, M. G. Schwacha, W. G. Cioffi, K. I. Bland and I. H. Chaudry, The aromatase inhibitor, 4-hydroxyandrostenedione, restores immune responses following trauma-hemorrhage in males and decreases mortality from subsequent sepsis,(2000) 347-353.
    Open DOISearch in Google Scholar
  50. J. Morales-Montor, C. Hallal-Calleros, M. C. Romano and R. T. Damian, Inhibition of p-450 aromatase prevents feminisation and induces protection during cysticercosis,(2002) 1379-1387; DOI: 10.1016/S0020-7519(02)00130-3.
    Open DOISearch in Google Scholar
  51. T. Watanabe, M. Sano, M. Toi, T. Saeki, K. Kanda, S. Miura, H. Inaji, H. Sono, H. Saeki, R. Nishimura and Y. Fujita, Late phase II study of exemestane in postmenopausal patients with breast cancer resistant to anti-estrogenic agents,(2002) 1211-1221.
    Search in Google Scholar
  52. M. Mello-Grand, V. Singh, C. Ghimenti, M. Scatolini, L. Regolo, E. Grosso, A. Zambelli, G. A. Da Prada, L. Villani, V. Fregoni, P. Baiardi, S. Marsoni, W. R. Miller, A. Costa and G. Chiorino, Gene expression profiling and prediction of response to hormonal neoadjuvant treatment with anastrozole in surgically resectable breast cancer,(2010) 399-411; DOI: 10.1007/s10549-010-0887-y.
    Open DOISearch in Google Scholar
  53. B. Karagöz, O. Bilgi, A. Alacacioğlu, A. Ozgün, O. Sayan, A. A. Erikçi and E. G. Kandemir, Mean platelet volume increase after tamoxifen, but not after anastrazole in adjuvant therapy of breast cancer,(2010) 199-202; DOI: 10.1007/s12032-009-9191-2.
    Open DOISearch in Google Scholar
  54. D. Generali, G. Bates, A. Berruti, M. P. Brizzi, L. Campo, S. Bonardi, A. Bersiga, G. Allevi, M. Milani, S. Aguggini, L. Dogliotti, A. H. Banham, A. L. Harris, A. Bottini and S. B. Fox, Immuno-modulation of FOXP3+ regulatory T cells by the aromatase inhibitor letrozole in breast cancer patients,(2009) 1046-1051; DOI: 10.1158/1078-0432.CCR-08-1507.
    Open DOISearch in Google Scholar
  55. Q. Zhang, D. Tang and H. Zhao, Immunological therapies can relieve aromatase inhibitor-reated joint symptoms in breast cancer survivors,(2010) 557-560; DOI: 10.1097/COC.0b013e3181cae782.
    Open DOISearch in Google Scholar
  56. J. Wang, Q. Zhang, S. Jin, M. Feng, X. Kang, S. Zhao, S. Liu and W. Zhao, Immoderate inhibition of estrogen by anastrozole enhances the severity of experimental polyarthritis,(2009) 398-405; DOI: 10.1016/j.exger.2009.03.003.
    Open DOISearch in Google Scholar
  57. M. N. Singh, P. L. Martin-Hirsch and F. L. Martin, The multiple applications of tamoxifen: an example pointing to SERM modulation being the aspirin of the 21st century,(2008) 144-148.
    Search in Google Scholar
  58. J. Komi and O. Lassila, Nonsteroidal anti-estrogens inhibit the functional differentiation of human monocyte-derived dendritic cells,(2000) 2875-2882.
    Open DOISearch in Google Scholar
  59. J. Komi, M. Möttönen, R. Luukkainen and O. Lassila, Non-steroidal anti-oestrogens inhibit the differentiation of synovial macrophages into dendritic cells,(2001) 185-191; DOI: 10.1093/rheumatology/40.2.185.
    Open DOISearch in Google Scholar
  60. S. Behjati and M. H. Frank, The effects of tamoxifen on immunity,(2009) 3076-3080.
    Open DOISearch in Google Scholar
  61. B. F. Bebo Jr, B. Dehghani, S. Foster, A. Kurniawan, F. J. Lopez and L. S. Sherman, Treatment with selective estrogen receptor modulators regulates myelin specific T-cells and suppresses experimental autoimmune encephalomyelitis,(2009) 777-790; DOI: 10.1002/glia.20805.
    Open DOISearch in Google Scholar
  62. D. Sereda and V. P. Werth, Improvement in dermatomyositis rash associated with the use of antiestrogen medication,(2006) 70-72.
    Search in Google Scholar
  63. M. Babina, F. Kirn, D. Hoser, D. Ernst, W. Rohde, T. Zuberbier and M. Worm, Tamoxifen counteracts the allergic immune response and improves allergen-induced dermatitis in mice,(2010) 1256-1265; DOI: 10.1111/j.1365-2222.2010.03472.x.
    Open DOISearch in Google Scholar
  64. W. M. Wu, J. L. Suen, B. F. Lin and B. L. Chiang, Tamoxifen alleviates disease severity and decreases double negative T cells in autoimmune MRL-lpr/lpr mice,(2000) 110-118; DOI: 10.1046/j.1365-2567.2000.00998.x.
    Open DOISearch in Google Scholar
  65. W. M. Wu, B. F. Lin, Y. C. Su, J. L. Suen and B. L. Chiang, Tamoxifen decreases renal inflammation and alleviates disease severity in autoimmune NZB/W F1 mice,(2000) 393-400; DOI: 10.1046/j.1365-3083.2000.00789.x.
    Open DOISearch in Google Scholar
  66. Z. M. Sthoeger, H. Zinger and E. Mozes, Beneficial effects of the anti-oestrogentamoxifen on systemic lupus erythematosus of (NZBxNZW)F1 female mice are associated with specific reduction of IgG3 autoantibodies,(2003) 341-346; DOI: 10.1136/ard.62.4.341.
    Open DOISearch in Google Scholar
  67. E. Peeva, J. Venkatesh and B. Diamond, Tamoxifen blocks estrogen-induced B cell maturation but not survival,(2005) 1415-1423.
    Open DOISearch in Google Scholar
  68. Y. Y. Dhaher, B. D. Greenstein, M. A. Khamashta and G. R. Hughes, Effects of oestradiol and the oestrogen antagonist Ici 182,780 on the delayed type hypersensitivity (DTH) index and on serum levels of IgM and IgG in ovariectomisedBalb/C and MRL/Mp-Lpr/Lpr mice, a model of systemic lupus erythematosus (SLE),(2001) 237-243.
    Open DOISearch in Google Scholar
  69. V. Paharkova-Vatchkova, R. Maldonado and S. Kovats, Estrogen preferentially promotes the differentiation of CD11c+ CD11b(intermediate) dendritic cells from bone marrow precursors,(2004) 1426-1436.
    Open DOISearch in Google Scholar
  70. S. Cuzzocrea, S. Bruscoli, C. Crisafulli, E. Mazzon, M. Agostini, C. Muià, E. Esposito, R. Di Virgilio, R. Meli, E. Vegeto, A. Maggi and C. Riccardi, Estrogen receptor antagonist fulvestrant (ICI 182,780) inhibits the anti-inflammatory effect of glucocorticoids,(2007) 132-144; DOI: 10.1124/mol.106.029629.
    Open DOISearch in Google Scholar
  71. N. I. Abdou, V. Rider, C. Greenwell, X. Li and B. F. Kimler, Fulvestrant (Faslodex), an estrogen selective receptor downregulator, in therapy of women with systemic lupus erythematosus. Clinical, serologic, bone density, and T cell activation marker studies: a double-blind placebo-controlled trial,(2008) 797.
    Search in Google Scholar
  72. S. N. Umathe, P. V. Dixit, M. M. Wanjari and M. P. Ullewar, Leuprolide—a GnRH agonist—prevents restraint stress-induced immunosuppression via sex steroid-independent peripheral mechanism in mice,(2008) 71-79; DOI: 10.1016/j.intimp.2007.10.011.
    Open DOISearch in Google Scholar
  73. G. L. Goldberg, C. G. King, R. A. Nejat, D. Y. Suh, O. M. Smith, J. C. Bretz, R. M. Samstein, J. A. Dudakov, A. P. Chidgey, S. Chen-Kiang, R. L. Boyd and M. R. van den Brink, Luteinizing hormone-releasing hormone enhances T cell recovery following allogeneic bone marrow transplantation,(2009) 5846-5854; DOI: 10.4049/?jimmunol.0801458.
    Open DOISearch in Google Scholar
  74. K. Szyllo, H. Tchorzewski, M. Banasik, E. Glowacka, P. Lewkowicz and A. Kamer-Bartosinska, The involvement of T lymphocytes in the pathogenesis of endometriotic tissues overgrowth in women with endometriosis,(2003) 131-138; DOI: 10.1080/0962935031000134842.
    Open DOISearch in Google Scholar
  75. H. N. Ho, H. F. Chen, S. U. Chen, K. H. Chao, Y. S. Yang, S. C. Huang, T. Y. Lee and T. J. Gill 3rd., Gonadotropin releasing hormone (GnRH) agonist induces down-regulation of the CD3+ CD25+ lymphocyte subpopulation in peripheral blood,(1995) 243-252.
    Open DOISearch in Google Scholar
  76. N. Umesaki, T. Tanaka, M. Miyama, K. Mizuno, N. Kawamura and S. Ogita, Increased natural killer cell activities in patients treated with gonadotropin releasing hormone agonist,(1999) 66-68; DOI: 10.1159/000010137.
    Open DOISearch in Google Scholar
  77. G. G. Garzetti, A. Ciavattini, M. Provinciali, M. Muzzioli, G. Di Stefano and N. Fabris, Natural cytotoxicity and GnRH agonist administration in advanced endometriosis: positive modulation on natural killer activity,(1996) 234-240; DOI: 10.1016/0029-7844(96)00146-9.
    Open DOISearch in Google Scholar
  78. M. E. Sabbioni, H. P. Siegrist, M. Bacchi, J. Bernhard, M. Castiglione, B. Thürlimann, H. Bonnefoi, L. Perey, R. Herrmann, A. Goldhirsch and C. Hürny, Association between immunity and prognostic factors in early stage breast cancer patients before adjuvant treatment,(2000) 279-287; DOI: 10.1023/A:1006379925343.
    Open DOISearch in Google Scholar
  79. A. Ray, V. Gupta, R. Kant, R. Yadav, A. K. Bahadur, S. L. D. Naik, B. K. Sharma and N. S. Murthy, T-lymphocytes in breast cancer: association with prognostic factors and response to treatment,(2003) 105-115.
    Search in Google Scholar
  80. E. Pavoni, G. Monteriù, D. Santapaola, F. Petronzelli, A. M. Anastasi, A. Pelliccia, V. D'Alessio, R. De Santis and O. Minenkova, Tumor-infiltrating B lymphocytes as an efficient source of highly specific immunoglobulins recognizing tumor cells,(2007) 70; DOI: 10.1186/1472-6750-7-70.
    Open DOISearch in Google Scholar
  81. V. N. Kristensen, C. J. Vaske, J. Ursini-Siegel, P. Van Loo, S. H. Nordgard, R. Sachidanandam, T. Sørlie, F. Wärnberg, V. D. Haakensen, A. Helland, B. Naume, C. M. Perou, D. Haussler, O. G. Troyanskaya and A. L. Børresen-Dale, Integrated molecular profiles of invasive breast tumors and ductal carcinoma in situ (DCIS) reveal differential vascular and interleukin signaling,(2012) 2802-2807; DOI: 10.1073/pnas.1108781108.
    Open DOISearch in Google Scholar
  82. S. C. Baumgarten and J. Frasor, Mini review: Inflammation: An instigator of more aggressive estrogen receptor (ER) positive breast cancers,(2012) 360-371; DOI: 10.1210/me.2011-1302.
    Open DOISearch in Google Scholar
  83. C. K. Osborne and R. Schiff, Mechanisms of endocrine resistance in breast cancer,(2011) 233-247; DOI: 10.1146/annurev-med-070909-182917.
    Open DOISearch in Google Scholar
  84. M. E. Grossmann, A. Ray, K. J. Nkhata, D. A. Malakhov, O. P. Rogozina, S. Dogan and M. P. Cleary, Obesity and breast cancer: status of leptin and adiponectin in pathological processes,(2010) 641-653; DOI: 10.1007/s10555-010-9252-1.
    Open DOISearch in Google Scholar
  85. H. S. Kim, C. K. Yom, H. J. Kim, J. W. Lee, J. H. Sohn, J. H. Kim, Y. L. Park and S. H. Ahn, Overexpression of p53 is correlated with poor outcome in premenopausal women with breast cancer treated with tamoxifen after chemotherapy,(2010) 777-788; DOI: 10.1007/s10549-009-0560-5.
    Open DOISearch in Google Scholar
DOI: https://doi.org/10.2478/v10007-012-0012-3 | Journal eISSN: 1846-9558 | Journal ISSN: 1330-0075
Journal RSS Feed
Language: English, Croatian, Slovenian
Page range: 141 - 155
Published on: Jun 28, 2012
Published by: Croatian Pharmaceutical Society
In partnership with: Paradigm Publishing Services
Keywords:
breast cancer,
SERMs,
tamoxifen,
aromatase inhibitors,
immunopharmacology
Related subjects:
Pharmacy,
Pharmacy, other

© 2012 Amitabha Ray, Monica Ficek, published by Croatian Pharmaceutical Society
This work is licensed under the Creative Commons License.

Volume 62 (2012): Issue 2 (June 2012)
Previous article
Next article